What Does Sangamo Therapeutics (SGMO) Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Summary
A leader in zinc finger-based genome editing, pursuing a new growth phase through the commercialization approval process for its Fabry disease therapy and a strategic refocus on neurological diseases.
Subscribe🏢 What kind of company is Sangamo Therapeutics?
Sangamo Therapeutics Inc. was founded in 1995 and is headquartered in Richmond, California. It is a genomics editing and gene therapy specialist. The company is a pioneer in 'Zinc Finger Protein' technology, which precisely targets specific DNA sequences, and uses this platform to develop various therapies that correct or modulate gene function. Recently, the company has moved into the regulatory filing stage for its Fabry disease therapy (ST-920), aiming to leap into commercialization, while expanding its business scope into intractable neurological diseases based on genetic insights.
💰 How does it make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Strategic Partnerships and Collaborations | About 92% | Joint development and licensing revenue from large pharmaceutical companies such as Eli Lilly and Pfizer |
| Interest Income and Other | About 8% | Interest on cash holdings and incidental service revenue |
Sangamo Therapeutics is currently a pre-commercialization company, and the vast majority of its revenue comes from milestone payments generated through licensing and collaboration agreements with global pharmaceutical companies. Revenue is subject to variability depending on recent clinical progress in the pipeline and technology out-licensing performance, and the annual revenue scale stands at approximately $39.5M.
Market Capitalization and Company Scale
The market capitalization is $73.6M, which is about About 0% of Samsung Electronics' market cap. The company employs 142 people people.
Sangamo Therapeutics has a market cap of approximately $73.6M, which is about About 0% of Samsung Electronics' market capitalization. Approximately 142 people specialized scientists and executives are working across global sites to translate genome editing technology into real therapeutic applications.
📈 Sangamo Therapeutics Outlook and Stock Price Trend
1-Year Price Performance
Analyst Consensus
52-Week Price RangeLooking ahead, Sangamo's core catalysts will be the final FDA approval of its Fabry disease therapy (ST-920) and the securing of a new partner for its hemophilia A program. The Fabry disease therapy, in particular, is targeting completion of its BLA submission by summer 2026, and accelerated approval is anticipated based on positive clinical data. Rather than the -31.6% metric, the announcement of follow-up clinical results and additional technology out-licensing deals aimed at improving the capital structure are expected to be the decisive drivers of the stock's direction. The company aims, over the long term, to successfully transform itself into a neurology-focused specialty biopharmaceutical company.
⚔️ Core Competitive Strengths and Risks
The company holds proprietary, foundational genome editing technology, and the successful commercialization of its lead pipeline is the key to a re-rating of corporate value.
💪 Core Competitive Strengths
⚠️ Core Risks
Key competitors include Sanofi (SNY), Takeda (TAK), and Amicus Therapeutics (FOLD), which are strong players in the Fabry disease market. The company also competes on technological superiority in gene editing with Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), and others.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| SNY | Sanofi ADR | $42.77 | +0.1% | $101.9B | 22.0 | 1.3 | 5.7% | 5.72% |
 BEAM | Beam Therapeutics Inc | $23.99 | -1.6% | $2.5B | - | 2.3 | -8.08% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| TAK | Takeda Pharmaceutical Co ADR | $18.26 | +0.8% | $58.1B | - | 1.2 | -2.22% | 3.51% |
 NTLA | Intellia Therapeutics Inc | $11.74 | -1.6% | $1.6B | - | 2.3 | -55.44% | - |
 CRSP | CRISPR Therapeutics AG | $51.72 | -1.0% | $5.0B | - | 2.9 | -26.09% | - |
✅ Investor Checkpoints
Here are three key checkpoints that investors must verify when considering Sangamo Therapeutics.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 💊 BLA Completion for Fabry Disease Therapy | Confirm whether the final regulatory filing submission for ST-920 is completed on schedule and enters the approval process. | Caution |
| 🤝 Securing a New Hemophilia A Partner | It is important to determine whether a new global pharmaceutical partner can be found to commercialize the hemophilia pipeline returned from Pfizer. | Neutral |
| 💰 Financing and Cash Reserves | Check whether sufficient liquidity is secured to sustain operations beyond 2026 and address going-concern concerns. | Caution |
Investors should note that, given the nature of clinical-stage biotech companies, the stock can swing extremely on approval results or financing news.
Sangamo Therapeutics is a company that, having built up its technology base over many years, is on the verge of reaping the fruits of commercialization. If the company navigates the financial crunch and successfully anchors its lead drug in the market, a powerful share-price rebound could be in store.
Check Sangamo Therapeutics' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free